Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint
The CD40 receptor and its ligand CD40L is one of the most critical molecular pairs of the
stimulatory immune checkpoints. Both CD40 and CD40L have a membrane form and a …
stimulatory immune checkpoints. Both CD40 and CD40L have a membrane form and a …
Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia
E Carballido, M Veliz, R Komrokji… - Cancer …, 2012 - journals.sagepub.com
Background The last decade witnessed the emergence of several therapeutic options for
patients with chronic lymphocytic leukemia (CLL) for first-line and relapsed settings. The vast …
patients with chronic lymphocytic leukemia (CLL) for first-line and relapsed settings. The vast …
One, two, three—p53, p63, p73 and chemosensitivity
M Müller, ES Schleithoff, W Stremmel, G Melino… - Drug resistance …, 2006 - Elsevier
Molecular links between apoptosis, tumorigenesis and drug resistance provide starting
points for new therapeutic approaches and for a targeted cancer therapy. The discovery of …
points for new therapeutic approaches and for a targeted cancer therapy. The discovery of …
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients
S Pesonen, I Diaconu, L Kangasniemi, T Ranki… - Cancer research, 2012 - AACR
The immunosuppressive environment of advanced tumors is a primary obstacle to the
efficacy of immunostimulatory and vaccine approaches. Here, we report an approach to arm …
efficacy of immunostimulatory and vaccine approaches. Here, we report an approach to arm …
Molecular and cellular mechanisms of CLL: novel therapeutic approaches
The mainstay of therapy of chronic lymphocytic leukemia (CLL) is cytotoxic chemotherapy;
however, CLL is still an incurable disease with resistance to therapy developing in the …
however, CLL is still an incurable disease with resistance to therapy developing in the …
c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches
DYH Hallaert, A Jaspers, CJ van Noesel… - Blood, The Journal …, 2008 - ashpublications.org
In lymph node (LN) proliferation centers in chronic lymphocytic leukemia (CLL), the
environment protects from apoptotic and cytotoxic triggers. Here, we aimed to define the …
environment protects from apoptotic and cytotoxic triggers. Here, we aimed to define the …
[HTML][HTML] Construction of a prognostic model of luteolin for endometrial carcinoma
J Zhao, W Jiao, X Sui, J Zou, J Wang… - American Journal of …, 2023 - ncbi.nlm.nih.gov
Objective: Endometrial cancer is one of the most common tumors of the female reproductive
system, and the existing treatment options for advanced and metastatic endometrial cancer …
system, and the existing treatment options for advanced and metastatic endometrial cancer …
Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges
CL Law, IS Grewal - Therapeutic targets of the TNF superfamily, 2009 - Springer
CD40 was originally identified as a receptor on B-cells that delivers contact-dependent T
helper signals to B-cells through interaction with CD40 ligand (CD40L, CD154). The pivotal …
helper signals to B-cells through interaction with CD40 ligand (CD40L, CD154). The pivotal …
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent …
R Lapalombella, L Andritsos, Q Liu… - Blood, The Journal …, 2010 - ashpublications.org
Chronic lymphocytic leukemia (CLL) involves a profound humoral immune defect and tumor-
specific humoral tolerance that directly contribute to disease morbidity and mortality. CD154 …
specific humoral tolerance that directly contribute to disease morbidity and mortality. CD154 …
Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia
M Trbusek, J Smardova, J Malcikova… - Journal of clinical …, 2011 - ascopubs.org
Purpose There is a distinct connection between TP53 defects and poor prognosis in chronic
lymphocytic leukemia (CLL). It remains unclear whether patients harboring TP53 mutations …
lymphocytic leukemia (CLL). It remains unclear whether patients harboring TP53 mutations …